Evidence map›Paper›PMID 31113476›Full record

Trial reportStem cell research & therapy2019

Treatment of knee osteoarthritis with intra-articular injection of autologous adipose-derived mesenchymal progenitor cells: a prospective, randomized, double-blind, active-controlled, phase IIb clinical trial.

Liangjing Lu, Chengxiang Dai, Zhongwen Zhang, Hui Du, Suke Li, Ping Ye, Qiong Fu, Li Zhang, Xiaojing Wu, Yuru Dong and 4 more

2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 145 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
145citing papers in PubMed, 19 pooled it
20.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02162693 phase2completednot on this map

A PhaseⅡb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis

TypeinterventionalSponsorShanghai AbelZeta Ltd.Ran2013 to 2016Enrolled53ConditionsKnee OsteoarthritisArmsMesenchymal progenitor cells, Sodium Hyaluronate
NCT05660824 phase4not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Effectiveness of Stromal Vascular Fraction (SVF) and Platelet -Rich Plasma (PRP) in Patients With Knee Osteoarthritis: Study Protocol for a Phase III, Prospective, Randomized, Controlled Multi-center Study : (SPOST Study)

TypeinterventionalSponsorAdrien SchwitzguebelRan2025 to 2027Enrolled108ConditionsOsteoarthritisArmsStromal Vascular Fraction infiltration, Plattelet Rich Plasma infiltration
3 · Its place in the literature

Who cites it

145 citing papers in PubMed, 19 syntheses or guidelines pooled it, 256 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Stem cell injections for osteoarthritis of the knee.The Cochrane database of systematic reviews · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Trial

85 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Liangjing LuDepartment of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai, 200001, People's Republic of China.
Chengxiang DaiCellular Biomedicine Group, Shanghai, China.
Zhongwen ZhangDepartment of Orthopedics, The General Hospital of Chinese People's Armed Police Forces, Beijing, China.
Hui DuDepartment of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai, 200001, People's Republic of China.
Suke LiCellular Biomedicine Group, Shanghai, China.
Ping YeDepartment of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai, 200001, People's Republic of China.
Qiong FuDepartment of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai, 200001, People's Republic of China.
Li ZhangCellular Biomedicine Group, Shanghai, China.
Xiaojing WuCellular Biomedicine Group, Shanghai, China.
Yuru DongDepartment of MRI, The General Hospital of Chinese People's Armed Police Forces, Beijing, China.
Yang SongDepartment of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai, 200001, People's Republic of China.
Dongbao ZhaoDepartment of Rheumatology, Changhai Hospital of Shanghai, Shanghai, China.
Yafei PangDepartment of Rheumatology, Changhai Hospital of Shanghai, Shanghai, China.
Chunde BaoDepartment of Rheumatology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle of Shandong Road, Huangpu District, Shanghai, 200001, People's Republic of China. baochunde_1678@126.com.
Shanghai Jiao Tong University · CNShanghai Cell Therapy Research Institute · CNChanghai Hospital · CNChinese People's Armed Police ForceChinese People's Armed Police General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHuman adipose-derived mesenchymal progenitor cells (haMPCs) are stem cells with multiple differentiation potential and immunomodulatory function. Re-Join® comprises in vitro expanded haMPCs from adipose tissue of patients combined with cell suspension solution. This study was undertaken to evaluate the efficacy and safety of Re-Join® in patients with symptomatic knee osteoarthritis (OA).

methodsPatients with Kellgren-Lawrence grade 1-3 knee OA were recruited from two centers and randomized to receive intra-articular injection of Re-Join® or HA. Pain and function were assessed by using WOMAC score, VAS, and SF-36. Magnetic resonance imaging (MRI) analysis was performed to measure cartilage repair. Adverse events (AEs) were collected.

resultsFifty-three patients were randomized. Significant improvements in WOMAC, VAS, and SF-36 scores were observed in both groups at months 6 and 12 compared with baseline. Compared with the HA group, significantly more patients achieved 50% improvement of WOMAC and a trend of more patients achieved a 70% improvement rate in Re-Join® group after 12 months. Meanwhile, there was notably more increase in articular cartilage volume of both knees in the Re-Join® group than in the HA group after 12 months as measured by MRI. AEs were comparable between two groups. Most AEs were mild and moderate except one SAE of right knee joint infection in the HA group.

conclusionsSignificant improvements in joint function, pain, quality of life, and cartilage regeneration were observed in Re-Join®-treated knee OA patients with good tolerance in a period of 12 months.

trial registrationClinicalTrials.gov Identifier: NCT02162693 . Registered 13 June 2014.

Indexed as

Mesenchymal Stem Cell TransplantationTransplantation, AutologousAdolescentAdultAgedDouble-Blind MethodFemaleHumansInjections, Intra-ArticularKnee JointMaleMesenchymal Stem CellsMiddle AgedOsteoarthritis, KneePain MeasurementProspective StudiesIntra-articular injectionKnee osteoarthritisMagnetic resonance imagingMesenchymal stem cellsWOMAC

Identifiers

PMID31113476
PMCPMC6528322
OpenAlexW2947662386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.